We are live on ! Find out more
OPNT

Opiant Pharmaceuticals, Inc. Common Stock
OPNT

Delisted

OPNT was delisted on the 1st of March, 2023.

Back to rankings

0 hedge funds and large institutions have $0 invested in Opiant Pharmaceuticals, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 37 → 0 (-37)

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

100% less capital invested

Capital invested by funds: $41.2M → $0 (-$41.2M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 36

Holders
–
Holders Change
-37
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
36
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
WSL
Western Standard LLC
California
-$8.6M
2
ACA
Apis Capital Advisors
New York
-$4.34M
3
Morgan Stanley
Morgan Stanley
New York
-$4.01M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$3.87M
5
Renaissance Technologies
Renaissance Technologies
New York
-$2.97M
Name Holding Trade Value Shares
Change 		Change in
Stake
WSL
1
Western Standard LLC
California
– -$8.6M -424,080 Closed
ACA
2
Apis Capital Advisors
New York
– -$4.34M -214,000 Closed
Morgan Stanley
3
Morgan Stanley
New York
– -$4.01M -197,652 Closed
Vanguard Group
4
Vanguard Group
Pennsylvania
– -$3.87M -190,773 Closed
Renaissance Technologies
5
Renaissance Technologies
New York
– -$2.97M -146,415 Closed
Wells Fargo
6
Wells Fargo
California
– -$2.77M -136,814 Closed
Dimensional Fund Advisors
7
Dimensional Fund Advisors
Texas
– -$2.03K -100,209 Closed
NYLIM
8
New York Life Investment Management
New York
– -$1.26M -61,912 Closed
CL
9
CSS LLC
Illinois
– -$1.24M -61,349 Closed
PHP
10
Parkman Healthcare Partners
Connecticut
– -$1.22M -59,943 Closed
RA
11
Ramius Advisors
New York
– -$1.12M -55,298 Closed
YCM
12
Yakira Capital Management
Connecticut
– -$1.1M -54,371 Closed
Geode Capital Management
13
Geode Capital Management
Massachusetts
– -$985K -48,591 Closed
BMCM
14
Black Maple Capital Management
Wisconsin
– -$985K -48,548 Closed
E
15
Ergoteles
New York
– -$876K -43,200 Closed
SSA
16
Schonfeld Strategic Advisors
New York
– -$858K -42,300 Closed
BlackRock
17
BlackRock
New York
– -$800K -39,425 Closed
Northern Trust
18
Northern Trust
Illinois
– -$784K -38,679 Closed
GF
19
Gabelli Funds
New York
– -$753K -37,119 Closed
GCIA
20
Gabelli & Co Investment Advisers
New York
– -$420K -20,700 Closed
Two Sigma Advisers
21
Two Sigma Advisers
New York
– -$377K -18,600 Closed
State Street
22
State Street
Massachusetts
– -$326K -16,085 Closed
FLC
23
Fifth Lane Capital
Texas
– -$304K -15,000 Closed
Citadel Advisors
24
Citadel Advisors
Florida
– -$287K -14,169 Closed
HM
25
Harvest Management
New York
– -$243K -12,000 Closed
1
2

OPNT Hedge Fund Activity: Q1 2023 in Review

0 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Opiant Pharmaceuticals, Inc. Common Stock (OPNT) for Q1 2023, worth a combined $0 — down 100% from $41.2M a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of OPNT and 0 opened new positions — a net loss of 36 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Western Standard LLC, exiting entirely with an estimated $8.6M sold.

  • 0 institutional investors held Opiant Pharmaceuticals, Inc. Common Stock (OPNT) as of Q1 2023, down from 37 in Q4 2022.
  • Funds reported $0 of Opiant Pharmaceuticals, Inc. Common Stock stock for Q1 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Opiant Pharmaceuticals, Inc. Common Stock positions in Q1 2023 and 36 closed out, a net change of -36 holders.
  • The largest Opiant Pharmaceuticals, Inc. Common Stock seller in Q1 2023 was Western Standard LLC, an estimated $8.6M sold.

Based on aggregated 13F filings for Q1 2023.